← Back to Screener
Lixte Biotechnology Holdings, Inc. Common Stock (LIXT)
Price$3.44
Favorite Metrics
Price vs S&P 500 (26W)-27.74%
Price vs S&P 500 (4W)21.00%
Market Capitalization$39.91M
All Metrics
Book Value / Share (Quarterly)$1.10
P/TBV (Annual)1.30x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.35
Price vs S&P 500 (YTD)-16.53%
EPS (TTM)$-1.21
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.21
EPS (Annual)$-1.24
ROI (Annual)-62.18%
Cash / Share (Quarterly)$0.58
ROA (Last FY)-47.19%
EBITD / Share (TTM)$-1.06
ROE (5Y Avg)-177.11%
Cash Flow / Share (Annual)$-0.35
P/B Ratio4.13x
P/B Ratio (Quarterly)3.25x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-5.64x
ROA (TTM)-115.21%
EPS Incl Extra (Annual)$-1.24
Current Ratio (Annual)3.88x
Quick Ratio (Quarterly)3.83x
3-Month Avg Trading Volume0.07M
52-Week Price Return203.61%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.62
P/S Ratio (Annual)199.54x
Asset Turnover (Annual)0.33x
52-Week High$6.26
EPS Excl Extra (Annual)$-1.24
Tangible BV CAGR (5Y)39.01%
26-Week Price Return-20.85%
Quick Ratio (Annual)3.83x
13-Week Price Return0.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.88x
Enterprise Value$39.908
Book Value / Share Growth (5Y)-22.92%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1425.00%
Cash / Share (Annual)$0.58
3-Month Return Std Dev86.37%
Net Income / Employee (TTM)$-3
ROE (Last FY)-62.18%
Net Interest Coverage (Annual)-3.43x
EPS Basic Excl Extra (Annual)$-1.24
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.21
ROI (TTM)-146.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.10
Price vs S&P 500 (52W)168.97%
Year-to-Date Return-12.60%
5-Day Price Return18.04%
EPS Normalized (Annual)$-1.24
ROA (5Y Avg)-144.80%
Net Profit Margin (Annual)-1425.00%
Month-to-Date Return11.89%
EBITD / Share (Annual)$-1.05
Operating Margin (Annual)-1325.00%
ROI (5Y Avg)-177.11%
EPS Basic Excl Extra (TTM)$-1.21
P/TBV (Quarterly)2.49x
P/B Ratio (Annual)3.25x
Book Value / Share (Annual)$1.10
Price vs S&P 500 (13W)-1.65%
Beta1.08x
Revenue / Share (TTM)$0.00
ROE (TTM)-146.69%
52-Week Low$0.64
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LIXTLixte Biotechnology Holdings, Inc. Common Stock | — | — | — | — | $3.44 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Lixte Biotechnology Holdings develops Protein Phosphatase 2A (PP2A) inhibitors designed to enhance combination cancer therapies. The company's lead candidate, LB-100, has demonstrated clinical anti-cancer activity with low toxicity and is intended to work alongside chemotherapy, radiation, and immune checkpoint inhibitors. Lixte is advancing LB-100 through clinical development across multiple cancer indications.